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Abstract
Background—The possibility that hyperglycemia accounts for the 2–3 fold higher risk of 
ischemic heart disease (IHD) in type 2 diabetes was explored by assessing the effect of intensive 
glucose lowering on IHD in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 
trial.
Methods—10,251 people (mean age = 62) with type 2 diabetes (mean duration = 10 years, mean 
A1c = 8.3%) were allocated to intensive or standard glycemic control targeting an A1c <6% or 7–
7.9% respectively. This intervention’s effect on IHD (fatal or non-fatal myocardial infarction, 
coronary revascularization, unstable angina, and new angina) was assessed during a mean active 
treatment period of 3.7 years followed by an additional 1.2 years.
© 2014 Elsevier Ltd. All rights reserved.
Address Correspondence to: Dr. H. C. Gerstein, Department of Medicine, Room 3V38, 1280 Main Street West, Hamilton, Ontario, 
L8S 4K1, Canada, Phone: (905) 521-2100, ext. 73371; FAX: (905) 521-4971, gerstein@mcmaster.ca. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Statement of Contributions
All authors participated in acquiring and interpreting the data. HCG and MEM wrote the first draft of the manuscript, MEM completed 
the statistical analyses, and F I-B, JL, CM, HAL, and GLB revised the manuscript and approved the final draft.
Declaration of Interests
MEM and GLB report no other disclosures.
HHS Public Access
Author manuscript
Lancet. Author manuscript; available in PMC 2015 November 29.
Published in final edited form as:













Results—Fewer participants allocated to the intensive versus standard care group experienced a 
myocardial infarction during both active treatment (HR = 0.80; 95% CI 0.67 – 0.96; P = 0.015) 
and full (active and additional) follow-up (HR = 0.84; 95% CI 0.72 – 0.97; P = 0.02). Similar 
findings were observed for a composite IHD outcome of myocardial infarction, coronary 
revascularization or unstable angina (HR = 0.89; 95% CI 0.79–0.99 and HR = 0.87; 95% CI 0.79 – 
0.96 during active treatment and full follow-up respectively)and for coronary revascularization 
(HR = 0.84; 95% CI 0.75–0.94), and unstable angina (HR = 0.81; 95% CI 0.67–0.97) during full 
follow-up. Adding A1C levels achieved during active treatment attenuated the significant hazard 
ratios to neutrality.
Conclusions—Glucose elevation is a modifiable risk factor for IHD in middle aged people with 
type 2 diabetes and other IHD risk factors.
Introduction
People with type 2 diabetes have a 2–3 fold higher incidence of ischemic heart disease 
(IHD) than people without diabetes, even after accounting for other IHD risk factors1, 2. 
Reasons for this relationship remain unclear. However as diabetes is defined on the basis of 
an elevated glucose level3, and as progressively higher A1c levels are related to 
progressively higher incidence of IHD4, an elevated glucose level may be an important 
contributing factor. This possibility is supported by the observation that 10 years of more 
versus less intensive glucose lowering reduced the 20 year risk of myocardial infarction 
(MI) by 15% in people with newly diagnosed type 2 diabetes5. It is also supported by a 
meta-analysis of data from the 4 large outcomes trials of more versus less intense glucose 
lowering (conducted by the investigators of these trials) which reported a 15% lower 
incidence of total MIs (95% CI 6–24) during a mean follow-up period of 4.4 years6.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a large North 
American trial of more versus less intense glucose lowering that was conducted in people 
with established type 2 diabetes and additional risk factors for cardiovascular disease. As 
previously reported the intervention had a nonsignificant effect on the primary composite 
cardiovascular outcome. However it also modestly reduced the incidence of nonfatal 
myocardial infarctions and increased the risk of death and particularly death from 
cardiovascular causes. The increased cardiovascular mortality remains unexplained, and 
exploratory analyses to date have not implicated severe hypoglycemia7, the degree or speed 
of glucose lowering8 or other potential causes9–11. Conversely the reduced rate of ischemic 
heart disease in ACCORD remains unexplored. The effect of the ACCORD glycemia 
intervention on indices of IHD including both fatal and nonfatal MI, angina and new onset 
angina, and the degree to which any of the above effects may be accounted for by the effect 
of the glycemia intervention on the A1c level during the active treatment period is therefore 
reported in this paper.
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The design and results of the ACCORD trial have been previously published12, 13. Briefly, 
10,251 men and women aged 40–79 years with type 2 diabetes of mean duration 10 years, a 
mean glycated hemoglobin (A1c) level of 8.3%, and either previous cardiovascular events or 
risk factors for cardiovascular disease were recruited from 77 clinical centers in the United 
States and Canada. Participants were randomly allocated to either intensive glucose-
lowering targeting an A1c level <6% or to standard glucose lowering targeting an A1c level 
of 7–7.9%; the same medications were available to achieve these targets in both groups. 
These participants were concomitantly enrolled in either a blood pressure trial (in which 
participants were randomly allocated to either more versus less intense blood pressure 
lowering)14 or a lipid trial (in which participants all had statin therapy optimized and were 
then allocated to the addition of either fenofibrate versus placebo)15 using a double factorial 
design. Follow-up occurred at least every 4 months to facilitate attainment and maintenance 
of the therapeutic goals and to ascertain the occurrence of outcomes and adverse effects. The 
ACCORD trial was sponsored by the National Heart, Lung and Blood Institute (NHLBI) 
and all participants provided written informed consent.
Outcomes and Course of the Trial
The prespecified primary outcome of the ACCORD trial was the first occurrence of nonfatal 
myocardial infarction, nonfatal stroke or cardiovascular death. Cardiovascular death was 
defined (in order of observed incidence during follow-up) as: death that was unexpected or 
presumed to be due to cardiovascular disease; fatal congestive heart failure; fatal myocardial 
infarction; fatal stroke: “other” cardiovascular disease; fatal procedure; or a fatal 
arrhythmia12, 13. Secondary outcomes included each component of the primary outcome; 
death from any cause; an expanded composite comprising the primary outcome or 
revascularization or hospitalization for heart failure; a composite of cardiovascular death, or 
nonfatal myocardial infarction or unstable angina; fatal or nonfatal stroke; and fatal or non-
fatal congestive heart failure. The ACCORD definitions of the foregoing outcomes are 
available in a supplementary appendix to a prior publication15. Coronary revascularization 
was defined as a percutaneous coronary intervention (with or without a stent) or coronary 
artery bypass surgery. Unstable angina was defined as self-reported new, accelerated or rest 
angina, plus ischemia on the electrocardiogram and/or evidence of stenosis on angiography, 
and new onset angina was defined as the first time an event was recorded on the case report 
form as “new onset exertional angina”. The primary outcome and its’ components were 
adjudicated centrally by adjudicators unaware of treatment group.
Accruing data were carefully scrutinized by the Data Safety and Monitoring Board which 
recommended that the intervention be discontinued after they detected an increased all-cause 
and cardiovascular mortality in the intensive glycemia group. This recommendation was 
accepted, and participants who had been allocated to the intensive glycemia regimen were 
switched to the standard regimen on February 5, 2008 after a mean follow-up period of 3.7 
years. These participants continued to be followed for a mean of 1.2 years within the 
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factorialized blood pressure or lipid ACCORD trials during which outcomes continued to be 
ascertained.
Statistical Analysis
All statistical analyses were done at the ACCORD Coordinating Center using SAS 9.3. 
Continuous data were summarized as means and standard deviations, medians and 
interquartile ranges, or counts and percentages. Event rates were estimated as the number of 
events divided by the total person years of follow-up and expressed as N per 100 person 
years. Analyses were conducted using an intent-to-treat approach based on all outcomes 
accrued from randomization until the date of transition (February 5, 2008), and from 
randomization until the end of follow-up. The mean or median A1c, blood pressure, LDL 
and serum creatinine levels, and the use of cardioprotective drugs at these 2 time-points 
were counted based on the last data that were available prior to these time-points. 
Cumulative incidence plots accounting for death as a competing risk16 were used to estimate 
the cumulative proportion of participants who had each event type during these 2 follow-up 
periods.
Analyses for this report of the effect of the glycemia intervention on IHD focused on fatal or 
nonfatal myocardial infarction; coronary revascularization; unstable angina; new onset 
angina; and 2 composite outcomes: a) the first occurrence of a myocardial infarction, 
coronary revascularization or unstable angina; and b) the first occurrence of a myocardial 
infarction or unstable angina. Fine and Gray’s approach17 for fitting proportional 
subdistribution hazard models to survival data with competing risks was used to estimate the 
hazard ratio and 95% confidence intervals during these 2 follow-up periods. These models 
included a term representing glycemia group assignment plus terms accounting for 
participation in the blood pressure or lipid trial, assignment to the intensive blood pressure 
intervention in the blood pressure trial, assignment to fenofibrate in the lipid trial, and the 
presence or absence of prior cardiovascular disease. To determine whether any effect of the 
intervention on analyzed outcomes could be attributable to the A1c difference achieved 
during the active (pre-transition) treatment period, an exploratory analysis was conducted in 
which the A1c levels achieved during this period were included as time-dependent 
covariates (i.e. the covariate changed when new results were obtained every 4 months) in the 
proportional subdistribution hazard models and the hazard ratios were re-estimated. P-values 
of < 0.05 were considered to be significant.
The funder (National Heart Lung and Blood Institute) participated in the design of the 
ACCORD study. All of the trial data were collected, stored and analyzed by the trial 
coordinating center at Wake Forest University on behalf of the investigators. All authors 
vouch for the accuracy and completeness of the reported data and are responsible for the 
decision to submit the manuscript.
Results
Participants were followed for a mean of 3.7 years until the date of transition and mean of 
4.8 years until the end of follow-up. As noted in Table 1, the mean age at randomization was 
62 years, 39% were women, 18% reported a prior myocardial infarction, 11% reported prior 
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angina, and 22% reported a prior revascularization. At the end of both the active glycemia 
treatment period (mean of 3.7 years) and the full follow-up period (mean of 4.8 years), 
participants allocated to the intensive or standard glycemia intervention had similar mean 
blood pressures, LDL cholesterol levels and serum creatinine levels, and similar proportions 
of participants in each group were using statins, renin-angiotensin system drugs (i.e. ACE 
inhibitors or angiotensin receptor blockers) and aspirin (Table 1). As previously published12 
a greater number of every class of glucose lowering drug (and combinations of drugs) was 
used in the intensive versus standard group at the end of the active treatment period.
The entire follow-up period included up to 26% more IHD events than the active period 
alone. As illustrated in Figure 1, fewer participants allocated to the intensive group versus 
the standard care group experienced a myocardial infarction (i.e. fatal or nonfatal) both 
during the active treatment period (1.15/100 person-years versus 1.41 per 100 person-years) 
and during the entire follow-up period (1.25/100 person-years versus 1.46 per 100 person-
years). Compared to the standard group, participants in the intensive group were 20% less 
likely to have a myocardial infarction during the active treatment period (HR = 0.80; 95% 
CI 0.67 – 0.96; P = 0.015) and 16% less likely to have one during the entire follow-up 
period (HR = 0.84; 95% CI 0.72 – 0.97; P = 0.02). As noted in Figure 1 similar findings 
were observed for the composite IHD outcome of the first occurrence of a myocardial 
infarction, coronary revascularization or unstable angina (HR = 0.89; 95% CI 0.79–0.99 and 
HR = 0.87; 95% CI 0.79 –0.96 for the 2 treatment periods respectively) and for coronary 
revascularization (HR 0.84; 95% CI 0.75–0.94) and unstable angina (HR 0.81; 95% CI 
0.67–0.97) for just the entire treatment period. Similar findings were also noted for the first 
occurrence of a nonfatal myocardial infarction, and for the composite of any myocardial 
infarction or unstable angina. No significant effect of the intervention was noted with 
respect to a fatal myocardial infarction or new angina. Cumulative incidence curves for 
myocardial infarction, coronary revascularization, unstable angina and the composite of 
these 3 IHD outcomes are shown in Figure 2 (Supplemental Figures 1–8 in the online 
appendix display the numbers at risk for each plot).
Adding the A1c level measured during the active treatment period as a time-dependent 
covariate attenuated all of the significant hazard ratios to neutrality and did not change the 
significance of the non significant hazard ratios (Figure 3).
Discussion
These analyses summarize the effect of approximately 3.7 years of targeting an A1c <6% 
versus 7 – 7.9% on IHD using life style approaches plus drugs that were available until 
2008. They show that randomization to intensive glucose lowering significantly reduced the 
5 year incidence of a composite IHD outcome by 13%, and specifically reduced the 
incidence of any myocardial infarction (i.e. fatal or non-fatal) by 16%, nonfatal myocardial 
infarction by 19%, coronary revascularization by 16%, and unstable angina by 19%.
These analyses were not prespecified in the ACCORD protocol. Nevertheless, the 
suggestion that glucose lowering using a variety of approaches reduces incident IHD is 
consistent with findings from other large outcomes trials that glucose lowering reduces the 
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incidence of fatal and non-fatal myocardial infarction in type 2 diabetes6. The fact that this 
effect was observed at the end of the active treatment period and was even stronger after a 
further 1.2 years of follow-up is consistent with at least one other outcomes trial conducted 
in people with type 2 diabetes5. Moreover, the observation that adjusting for the A1c levels 
collected during the pre-transition period renders all of these effects statistically insignificant 
is consistent with the hypothesis that the degree of glucose lowering or some closely related 
factor may account for the effect of the intervention on IHD. Finally the effect was 
consistent across different measures of IHD. When viewed in light of a recent study showing 
that individuals with genetic markers of hyperglycemia had higher glucose levels and were 
also more likely to develop cardiovascular disease18 than those without these makers, these 
findings suggest that glucose elevation is a modifiable risk factor for IHD.
The beneficial effect of the intensive glycemia intervention on IHD is at odds with the 
ACCORD finding of increased death from cardiovascular causes with the intensive versus 
standard intervention. It is also at odds with the observation in the current analysis that the 
intensive intervention reduced all of the indices of IHD except for fatal MI. One possible 
explanation for the discrepancy is suggested by the previously published epidemiologic 
analysis of ACCORD which reported that much of the mortality in the intensive group 
occurred in those people whose A1c levels did not decrease from baseline, despite allocation 
to the intensive glycemic intervention7. When viewed in light of the current analysis 
showing that glucose lowering accounts for reduced IHD, those individuals whose glucose 
levels did not fall in response to the intervention may have been harmed by persistent, futile 
attempts to lower glucose levels due to unknown behavioural or biologic factors. 
Alternatively, as suggested in a recent editorial, the mortality signal in ACCORD may have 
been a chance finding11 – a possibility supported by the inability to identify a specific 
explanation to date7, 8, 10. It is also possible that some of the fatal MIs were misclassified as 
cardiovascular deaths not due to an MI. Regardless of the explanation, the fact more than 
80% of the cardiovascular deaths were adjudicated as not being attributable to a myocardial 
infarction (i.e. most of them were either unexpected deaths or due to presumed 
cardiovascular disease)12, 13, and the reduced risk of IHD events with the intensive glycemia 
intervention demonstrated by these analyses suggest that IHD may not be related to the 
mortality signal observed in the ACCORD intensive group.
It is important to note that these analyses were not preplanned and as such the current 
findings may have occurred by chance and hence may not be reproducible in other studies. 
Indeed, the large number of statistical tests conducted, and the overlap between the various 
indices of IHD mean that the reported findings may well have occurred by chance alone. 
Moreover the relatively few fatal myocardial infarctions did not provide enough power to 
clearly estimate the effect of the intervention on fatal IHD or to rule out the possibility of 
divergent effects on fatal versus nonfatal IHD. Strengths of these analyses include the 
randomized design, the large number of nonfatal events, and the high ascertainment of 
outcomes.
Whereas these findings suggest that glucose lowering interventions can reduce IHD, they do 
not nullify the prior observation that any overall cardiovascular benefits of 3.7 years of 
intensive glycemic control are outweighed by fatal harms. Nevertheless, they are consistent 
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with the hypothesis that dysglycemia is causally related to IHD and strongly indicate the 
need for further elucidation of this relationship.
Supplementary Material
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Research in Context Panel
Systematic Review
The effect of intensive glucose lowering on cardiovascular outcomes in people with type 
2 diabetes remains unclear. To date, only 4 large outcomes trials were identified that 
allocated people with type 2 diabetes to either more intensive versus less intensive 
glucose lowering and assessed the effect of the intervention on a variety of 
cardiovascular outcomes. A meta-analysis of data from these 4 trials reported that 
myocardial infarctions (i.e. fatal or nonfatal) were reduced by 15% (95% CI 6–24) during 
a mean follow-up period of 4.4 years6 whereas the meta-analyzed effect on strokes (fatal 
or nonfatal) did not differ from neutrality.
Interpretation
The effect of intensive glycemic control on all of the indices of ischemic heart disease 
that were measured in the ACCORD trial is analyzed in this report. Intensive glycemic 
control reduced the risk of myocardial infarctions, coronary revascularization, unstable 
angina, and a composite of myocardial infarction, coronary revascularization or unstable 
angina during a mean active treatment period of 3.7 years and a total follow-up period of 
4.9 years. Further elucidation of this relationship may identify individuals in whom the 
benefit of such an approach would clearly outweigh any harms.
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Figure 1. Ischemic Heart Disease Incidence and Hazard Ratios
Forest Plot of Incidence and Hazard Ratios. The number of events, annual incidence (%/
year), hazard ratios with 95% confidence intervals and P values are show for each treatment 
group from baseline until the end of the intervention trial (i.e. pre-transition), and from 
baseline until the end of the ACCORD trial (i.e. active plus additional follow-up). All 
analyses use the intent-to-treat approach, include the initial occurrence of each listed event, 
and account for competing risks due to deaths. Unstable angina includes new-onset angina, 
accelerated angina or rest angina. The numbers of the composite outcome of any MI or 
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unstable angina shown in the figure differ from those in a prior report12 due to a typographic 
error; the numbers in the prior report referred to non-stroke CV death, or nonfatal MI or 
unstable angina.
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Event Curves. The incidence of events in the intensive and standard glycemia groups from 
the time of randomization until the transition date (accounting for competing risk due to 
death) and until the end of the ACCORD trial is shown.
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Figure 3. Ischemic Heart Disease Incidence and Hazard Ratios After Adjustment for Pre-
transition A1c Levels
Forest Plot and Hazard Ratios Adjusted for Pre-transition A1c Levels. Hazard ratios 
adjusted for the pre-transition A1c levels as a time-varying covariate and account for 
competing risk due to death.
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Baseline Age (yrs) 62 (7) 62 (7)
Females 1983 (38.7%) 1969 (38.4%)
Prior Myocardial Infarction at Baseline 909 (17.7%) 925 (18.1%)
Prior Angina at Baseline 608 (11.9%) 560 (10.9%)
Prior Revascularization at Baseline 1185 (23.1%) 1112 (21.7%)
Until Transition
  Last A1c, Mean (SD) 6.6 (1.0) 7.7 (1.1)
  Last A1c, Median (IQR) 6.4 (6.0 – 7.0) 7.5 (7.0 – 8.2)
  Median Yrs Follow-up (IQR)* 3.7 (2.8 – 4.5) 3.7 (2.9 – 4.5)
  Mean Yrs Follow-up (SD)* 3.7 (1.4) 3.7 (1.4)
  Total Person Years of Follow-up 19,497 19,535
  Last ACE-I or ARB use 1830 (37.0) 1874 (37.6%)
  Last Statin use 3829 (74.7) 3833 (74.9)
  Last ASA use 3020 (58.9) 3002 (58.6)
  Last SBP (mm) 128 (17) 129 (17)
  Last DBP (mm) 67 (11) 68 (11)
  Last LDL (mg/dl) 91 (34) 91 (35)
  Last Serum Creatinine (mg/dl) 1.1 (0.4) 1.1 (0.4)
Until Study End
  LastA1c, Mean (SD) 7.3 (1.2) 7.8 (1.2)
  Last A1c, Median (IQR) 7.1 (6.5 – 7.9) 7.6 (7.0 – 8.4)
  Median Yrs Follow-up (IQR)** 4.8 (4.0 – 5.7) 4.8 (4.0 – 5.7)
  Mean Yrs Follow-up (SD)** 4.8 (1.6) 4.7 (1.6)
  Total Person Years of Follow-up 25,048 25,162
  Last ACE-I or ARB use 1855 (37.2) 1915 (38.3%)
  Last Statin use 3819 (74.5) 3843 (75.0)
  Last ASA use 3133 (61.1) 3156 (61.6)
  Last SBP (mm) 129 (18) 129 (17)
  Last DBP (mm) 68 (11) 68 (10)
  Last LDL (mg/dl) 89 (34) 89 (34)
  Last Serum Creatinine (mg/dl) 1.1 (0.4) 1.1 (0.5)
*
defined as time from randomization until initial occurrence of primary outcome, censoring date, or last day of pre-transition period (February 4, 
2008);
**
defined as time from randomization until initial occurrence of primary outcome, censoring date, or exit visit.
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